Cargando…

VE1 immunohistochemistry predicts BRAF V600E mutation status and clinical outcome in colorectal cancer

AIM: VE1 is a monoclonal antibody detecting mutant BRAF(V600E) protein by immunohistochemistry. Here we aim to determine the inter-observer agreement and concordance of VE1 with mutational status, investigate heterogeneity in colorectal cancers and metastases and determine the prognostic effect of V...

Descripción completa

Detalles Bibliográficos
Autores principales:	Schafroth, Christian, Galván, José A., Centeno, Irene, Koelzer, Viktor H., Dawson, Heather E., Sokol, Lena, Rieger, Gregor, Berger, Martin D., Hädrich, Marion, Rosenberg, Robert, Nitsche, Ulrich, Schnüriger, Beat, Langer, Rupert, Inderbitzin, Daniel, Lugli, Alessandro, Zlobec, Inti
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2015
Materias:	Research Paper: Pathology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4747166/ https://www.ncbi.nlm.nih.gov/pubmed/26496026

Ejemplares similares

CD8/CD45RO T-cell infiltration in endoscopic biopsies of colorectal cancer predicts nodal metastasis and survival
por: Koelzer, Viktor H, et al.
Publicado: (2014)

TWIST1 and TWIST2 promoter methylation and protein expression in tumor stroma influence the epithelial-mesenchymal transition-like tumor budding phenotype in colorectal cancer
por: Galván, José A., et al.
Publicado: (2014)

Investigation of IL-23 (p19, p40) and IL-23R identifies nuclear expression of IL-23 p19 as a favorable prognostic factor in colorectal cancer: a retrospective multicenter study of 675 patients
por: Helbling, Melina, et al.
Publicado: (2014)

CDX2 in colorectal cancer is an independent prognostic factor and regulated by promoter methylation and histone deacetylation in tumors of the serrated pathway
por: Graule, Janina, et al.
Publicado: (2018)

Tumor Budding in Upper Gastrointestinal Carcinomas
por: Koelzer, Viktor H., et al.
Publicado: (2014)

Intratumoural budding (ITB) in preoperative biopsies predicts the presence of lymph node and distant metastases in colon and rectal cancer patients
por: Zlobec, I, et al.
Publicado: (2014)

Utility of BRAF VE1 Immunohistochemistry as a Screening Tool for Colorectal Cancer Harboring BRAF V600E Mutation
por: Kwon, Jeong-Hwa, et al.
Publicado: (2018)

Loss of Cdx2 Expression in Primary Tumors and Lymph Node Metastases is Specific for Mismatch Repair-Deficiency in Colorectal Cancer
por: Dawson, Heather, et al.
Publicado: (2013)

VE1 Immunohistochemistry Improves the Limit of Genotyping for Detecting BRAF(V600E) Mutation in Papillary Thyroid Cancer
por: Choden, Sonam, et al.
Publicado: (2020)

VE1 immunohistochemistry is an adjunct tool for detection of BRAF (V600E) mutation: Validation in thyroid cancer patients
por: Rashid, Faiza A., et al.
Publicado: (2020)

Loss of tapasin correlates with diminished CD8(+) T-cell immunity and prognosis in colorectal cancer
por: Sokol, Lena, et al.
Publicado: (2015)

Role of Intra- and Peritumoral Budding in the Interdisciplinary Management of Rectal Cancer Patients
por: Zlobec, Inti, et al.
Publicado: (2012)

BRAF Inhibition in BRAF(V600)-Mutant Gliomas: Results From the VE-BASKET Study
por: Kaley, Thomas, et al.
Publicado: (2018)

A UK feasibility and validation study of the VE1 monoclonal antibody immunohistochemistry stain for BRAF-V600E mutations in metastatic melanoma
por: Lo, Michelle Chin I, et al.
Publicado: (2016)

Accumulation of FOXP3+T-cells in the tumor microenvironment is associated with an epithelial-mesenchymal-transition-type tumor budding phenotype and is an independent prognostic factor in surgically resected pancreatic ductal adenocarcinoma
por: Wartenberg, Martin, et al.
Publicado: (2015)

BRAF V600E mutation and BRAF VE1 immunoexpression profiles in different types of glioblastoma
por: Tosuner, Zeynep, et al.
Publicado: (2018)

Next-generation tissue microarray (ngTMA) increases the quality of biomarker studies: an example using CD3, CD8, and CD45RO in the tumor microenvironment of six different solid tumor types
por: Zlobec, Inti, et al.
Publicado: (2013)

Immunohistochemistry with the anti-BRAF V600E (VE1) antibody: impact of pre-analytical conditions and concordance with DNA sequencing in colorectal and papillary thyroid carcinoma
por: Dvorak, Katerina, et al.
Publicado: (2014)

Immunohistochemistry with Anti-BRAF V600E (VE1) Mouse Monoclonal Antibody is a Sensitive Method for Detection of the BRAF V600E Mutation in Colon Cancer: Evaluation of 120 Cases with and without KRAS Mutation and Literature Review
por: Dvorak, Katerina, et al.
Publicado: (2017)

Validation of Immunohistochemistry for the Detection of BRAF V600E-Mutated Lung Adenocarcinomas
por: Gow, Chien-Hung, et al.
Publicado: (2019)

Heterogeneity analysis of Metastasis Associated in Colon Cancer 1 (MACC1) for survival prognosis of colorectal cancer patients: a retrospective cohort study
por: Koelzer, Viktor H, et al.
Publicado: (2015)

Proper paraffin slide storage is crucial for translational research projects involving immunohistochemistry stains
por: Economou, Mary, et al.
Publicado: (2014)

Immunohistochemistry is highly sensitive and specific for detection of BRAF V600E mutation in pleomorphic xanthoastrocytoma
por: Ida, Cristiane M, et al.
Publicado: (2013)

BRAF‐V600E immunohistochemistry in a large series of glial and glial–neuronal tumors
por: Breton, Quentin, et al.
Publicado: (2017)

Clinical significance of immunohistochemistry to detect BRAF V600E mutant protein in thyroid tissues
por: Zhang, Yini, et al.
Publicado: (2021)

BRAF V600E Immunohistochemistry Predicts Prognosis of Patients with Cutaneous Melanoma in Thai population
por: Meevassana, Jiraroch, et al.
Publicado: (2022)

Epithelial mesenchymal transition and tumor budding in aggressive colorectal cancer: Tumor budding as oncotarget
por: Zlobec, Inti, et al.
Publicado: (2010)

The battle for prognosis at the invasive front of colorectal cancer
por: Lugli, Alessandro, et al.
Publicado: (2020)

Comparison of Immunohistochemistry and Direct Sanger Sequencing for Detection of the BRAF(V600E) Mutation in Thyroid Neoplasm
por: Oh, Hye-Seon, et al.
Publicado: (2018)

Reflectance confocal microscopy features of BRAF V600E mutated thin melanomas detected by immunohistochemistry
por: Urvanegia, Ana Claudia, et al.
Publicado: (2017)

Update on the current opinion, status and future development of digital pathology in Switzerland in light of COVID-19
por: Koelzer, Viktor Hendrik, et al.
Publicado: (2022)

Is immunohistochemistry of BRAF V600E useful as a screening tool and during progression disease of melanoma patients?
por: Schirosi, Laura, et al.
Publicado: (2016)

Immunohistochemistry cannot replace DNA analysis for evaluation of BRAF V600E mutations in papillary thyroid carcinoma
por: Szymonek, Monika, et al.
Publicado: (2017)

Immunohistochemistry as an accurate tool for the assessment of BRAF V600E and TP53 mutations in primary and metastatic melanoma
por: Rusu, Stefan, et al.
Publicado: (2021)

Expression analysis of LC3B and p62 indicates intact activated autophagy is associated with an unfavorable prognosis in colon cancer
por: Niklaus, Monique, et al.
Publicado: (2017)

Usefulness of BRAF VE1 immunohistochemistry in non–small cell lung cancers: a multi-institutional study by 15 pathologists in Korea
por: Chang, Sunhee, et al.
Publicado: (2022)

Loss of Raf-1 kinase inhibitor protein (RKIP) is strongly associated with high-grade tumor budding and correlates with an aggressive phenotype in pancreatic ductal adenocarcinoma (PDAC)
por: Karamitopoulou, Eva, et al.
Publicado: (2013)

NRAS(Q61R), BRAF(V600E) immunohistochemistry: a concomitant tool for mutation screening in melanomas
por: Uguen, Arnaud, et al.
Publicado: (2015)

Tumour budding and its clinical implications in gastrointestinal cancers
por: Zlobec, Inti, et al.
Publicado: (2020)

Detection of BRAF V600E Mutation in Ganglioglioma and Pilocytic Astrocytoma by Immunohistochemistry and Real-Time PCR-Based Idylla Test
por: Durślewicz, Justyna, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_it9pm6ilfb3lkr7u7f3nj1csod